Review
. 2008 Feb;107(3):309-30. doi: 10.1007/s10549-007-9556-1. Epub 2007 Mar 22. An overview of prognostic factors for long-term survivors of breast cancerAffiliations
AffiliationItem in Clipboard
Review
An overview of prognostic factors for long-term survivors of breast cancerIsabelle Soerjomataram et al. Breast Cancer Res Treat. 2008 Feb.
. 2008 Feb;107(3):309-30. doi: 10.1007/s10549-007-9556-1. Epub 2007 Mar 22. AffiliationItem in Clipboard
AbstractBackground: Numerous studies have examined prognostic factors for survival of breast cancer patients, but relatively few have dealt specifically with 10+-year survivors.
Methods: A review of the PubMed database from 1995 to 2006 was undertaken with the following inclusion criteria: median/mean follow-up time at least 10 years; overall survival and/or disease-specific survival known; and relative risk and statistical probability values reported. In addition, we used data from the long-standing Eindhoven Cancer Registry to illustrate survival probability as indicated by various prognostic factors.
Results: 10-year breast cancer survivors showed 90% 5-year relative survival. Tumor size, nodal status and grade remained the most important prognostic factors for long-term survival, although their role decreased over time. Most studies agreed on the long-term prognostic values of MI (mitotic index), LVI (lymphovascular invasion), Her2-positivity, gene profiling and comorbidity for either all or a subgroup of breast cancer patients (node-positive or negative). The roles of age, socioeconomic status, histological type, BRCA and p53 mutation were mixed, often decreasing after correction for stronger prognosticators, thus limiting their clinical value. Local and regional recurrence, metastases and second cancer may substantially impair long-term survival. Healthy lifestyle was consistently related to lower overall mortality.
Conclusions: Effects of traditional prognostic factors persist in the long term and more recent factors need further follow-up. The prognosis for breast cancer patients who have survived at least 10 years is favourable and increases over time. Improved long-term survival can be achieved by earlier detection, more effective modern therapy and healthier lifestyle.
FiguresFig. 1
Proportion of breast cancer patients…
Fig. 1
Proportion of breast cancer patients (3-year moving average) diagnosed between 1973 and 1993…
Fig. 1Proportion of breast cancer patients (3-year moving average) diagnosed between 1973 and 1993 who survived 10 years or longer in Southeastern Netherlands
Fig. 2
Relative survival of breast cancer…
Fig. 2
Relative survival of breast cancer patients (n: 13,279) diagnosed in 1990–2002 and followed…
Fig. 2Relative survival of breast cancer patients (n: 13,279) diagnosed in 1990–2002 and followed until 2004, according to age at diagnosis in southeastern Netherlands
Fig. 3
Conditional 5-year relative survival (calculated…
Fig. 3
Conditional 5-year relative survival (calculated using period analysis [22] of breast cancer patients…
Fig. 3Conditional 5-year relative survival (calculated using period analysis [22] of breast cancer patients diagnosed in southern Netherlands in 1985–2002 and followed until 2004, according to age. (Dashed line): diagnosed at 25–49 years, (solid line): diagnosed at 50–74 years
Fig. 4
Cumulative survival proportion of breast…
Fig. 4
Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–1994…
Fig. 4Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–1994 and followed until 2004, according to tumor size (based on pathological diagnosis). ■ tumor size: <2 cm (n: 3263) • tumor size: 2–5 cm (n: 3420) ▴ tumor size: >5 cm (n: 474) x tumor size: involvement of skin (n: 1133) and unknown/not applicable tumor size: 1410
Fig. 5
Cumulative survival proportion of breast…
Fig. 5
Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–1994…
Fig. 5Cumulative survival proportion of breast cancer patients diagnosed in southern Netherlands in 1970–1994 and followed until 2004, according to nodal status (based on pathological diagnosis). ■ node negative (n: 4452) • node status: 1–3 positive nodes (n: 3266) ▴ node status: 4–9 positive nodes (n: 255) x node status: 10+ positive nodes (n: 189), unknown/not applicable node status: 1538
Fig. 6
Cumulative survival of breast cancer…
Fig. 6
Cumulative survival of breast cancer patients diagnosed in southern Netherlands in 1970–1994 and…
Fig. 6Cumulative survival of breast cancer patients diagnosed in southern Netherlands in 1970–1994 and followed-up until 2004, according to second cancer. Follow-up for patients with second cancer begins at the date of second cancer diagnosis. ■ no second cancer (n: 8137) • second breast cancer (n: 744) ▴ second non-breast cancer (n: 819)
Similar articlesMirza AN, Mirza NQ, Vlastos G, Singletary SE. Mirza AN, et al. Ann Surg. 2002 Jan;235(1):10-26. doi: 10.1097/00000658-200201000-00003. Ann Surg. 2002. PMID: 11753038 Free PMC article. Review.
Di Saverio S, Gutierrez J, Avisar E. Di Saverio S, et al. Breast Cancer Res Treat. 2008 Oct;111(3):541-7. doi: 10.1007/s10549-007-9809-z. Epub 2007 Nov 18. Breast Cancer Res Treat. 2008. PMID: 18026874
Kato T, Kimura T, Miyakawa R, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T. Kato T, et al. Br J Cancer. 2000 Jan;82(2):404-11. doi: 10.1054/bjoc.1999.0934. Br J Cancer. 2000. PMID: 10646896 Free PMC article.
Truong PT, Yong CM, Abnousi F, Lee J, Kader HA, Hayashi A, Olivotto IA. Truong PT, et al. J Am Coll Surg. 2005 Jun;200(6):912-21. doi: 10.1016/j.jamcollsurg.2005.02.010. J Am Coll Surg. 2005. PMID: 15922205
Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN. Hanrahan EO, et al. J Clin Oncol. 2006 May 1;24(13):2113-22. doi: 10.1200/JCO.2005.02.8035. J Clin Oncol. 2006. PMID: 16648513 Review.
Vieira-Monteiro Hde A, Freitas-Alves DR, Sobral-Leite M, Delou JM, Goulart-Citrangulo SM, do Nascimento CT, E Castro TN, Koifman S, Perini JA, Vianna-Jorge R. Vieira-Monteiro Hde A, et al. Cancer Biol Ther. 2016 Jun 2;17(6):674-83. doi: 10.1080/15384047.2016.1190486. Cancer Biol Ther. 2016. PMID: 27195611 Free PMC article.
Wang XY, Zheng ZX, Sun Y, Bai YH, Shi YF, Zhou LX, Yao YF, Wu AW, Cao DF. Wang XY, et al. World J Gastrointest Oncol. 2019 Apr 15;11(4):335-347. doi: 10.4251/wjgo.v11.i4.335. World J Gastrointest Oncol. 2019. PMID: 31040898 Free PMC article.
Yin M, Verschraegen C, Vincent VH, Patel SM, George T, Truica CI. Yin M, et al. Medicine (Baltimore). 2020 Jan;99(3):e18745. doi: 10.1097/MD.0000000000018745. Medicine (Baltimore). 2020. PMID: 32011455 Free PMC article.
Yu XQ, De Angelis R, Luo Q, Kahn C, Houssami N, O'Connell DL. Yu XQ, et al. BMC Cancer. 2014 Dec 11;14:936. doi: 10.1186/1471-2407-14-936. BMC Cancer. 2014. PMID: 25494610 Free PMC article.
Domanitskaya N, Wangari-Talbot J, Jacobs J, Peiffer E, Mahdaviyeh Y, Paulose C, Malofeeva E, Foster K, Cai KQ, Zhou Y, Egleston B, Hopper-Borge E. Domanitskaya N, et al. Br J Cancer. 2014 Aug 12;111(4):696-707. doi: 10.1038/bjc.2014.326. Epub 2014 Jun 17. Br J Cancer. 2014. PMID: 24937672 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3